Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Study Evaluates Population-Wide Testing, Early Treatment for HIV Prevention

Published: Tuesday, October 01, 2013
Last Updated: Tuesday, October 01, 2013
Bookmark and Share
NIH co-funded trial will build on results of landmark HPTN 052 study.

A study in South Africa and Zambia will assess whether house-to-house voluntary HIV testing and prompt treatment of HIV infection, along with other proven HIV prevention measures, can substantially reduce the number of new HIV infections across communities.

The trial, Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART), or HPTN 071, is sponsored and co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The trial is funded primarily by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), administered by the Office of the Global AIDS Coordinator.

The PopART study will build on the results of the landmark, NIAID-funded HPTN 052 trial(http://www.niaid.nih.gov/news/newsreleases/2011/Pages/HPTN052.aspx), which found that HIV-infected individuals who start treatment early, when their immune systems are relatively healthy, dramatically reduce the risk of transmitting the virus to their heterosexual partners.

"Through this new study, we aim to learn whether the treatment of HIV-infected individuals as a form of HIV prevention, an approach previously tested in roughly 1,800 heterosexual couples where one partner was infected, will be just as effective when implemented across an entire adult population," said NIAID Director Anthony S. Fauci, M.D. "The study also will tell us whether this method of delivering population-wide HIV treatment as prevention is feasible and cost-effective."

The trial is being conducted in South Africa and Zambia because the HIV prevalence in those countries is among the highest in the world. An estimated 12.5 percent of adults in Zambia and 17.3 percent of adults in South Africa are infected.

Leading the study are Richard Hayes, D.Sc., professor of epidemiology and international health at the London School of Hygiene and Tropical Medicine, and Sarah J. Fidler, Ph.D., reader in the Department of Medicine at Imperial College London.

"Mathematical models indicate that if a high proportion of a population can be tested for HIV, and those found to be infected are offered treatment right away, then the rate of new HIV infections could decrease substantially over time," said Dr. Hayes. "The PopART study is assessing whether this approach works and whether the benefits outweigh the costs - information that could help guide public health policy."

The PopART study investigators have designed an HIV prevention package that includes
• Door-to-door, voluntary HIV testing offered at annual intervals
• Linkage of those who test positive for the virus to care at local health centers
• Promotion of voluntary medical circumcision to men who are not HIV-infected
• Promotion of steps to prevent mother-to-child HIV transmission
• Referral of individuals with other sexually transmitted infections to treatment
• Provision of condoms

The PopART trial will involve 21 communities in South Africa and Zambia with a total population of 1.2 million. The study team has randomly assigned each community to one of three groups.

One group of communities will receive the HIV prevention package along with the opportunity for HIV-infected individuals to begin treatment as soon as they test positive for the virus.

The second group will receive the same HIV prevention package, and infected individuals will be offered treatment at the stage of infection recommended by their country's HIV treatment guidelines. The third group will serve as a control and will receive existing HIV prevention and testing services along with HIV care and treatment according to current national guidelines for their country.

The study team will measure the impact of the two HIV prevention packages by determining the number of new HIV infections among a representative sample of 52,500 adults drawn from the 21 study communities and followed for three years. The study is expected to end in 2019.

The study research is being conducted by investigators at the NIH-funded HIV Prevention Trials Network (HPTN), the London School of Hygiene & Tropical Medicine, Imperial College London, the Zambia AIDS-Related Tuberculosis Project and the Desmond Tutu TB Centre of South Africa.

PEPFAR partners will provide HIV care and treatment to the study communities under the direction of the U.S. Agency for International Development and the U.S. Centers for Disease Control and Prevention.

In addition to PEPFAR and NIAID, study funders include the International Initiative for Impact Evaluation with support from the Bill & Melinda Gates Foundation, as well as the National Institute on Drug Abuse and the National Institute of Mental Health, both part of NIH.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Significant Expansion Of Data Available In The Genomic Data Commons
Cancer genomic profile information from 18,000 adult cancer patients will be added to the database.
Wednesday, June 29, 2016
Some Women With PCOS May Have Adrenal Disorder
Researchers at NIH have found that a subgroup of women with PCOS, a leading cause of infertility, may produce excess adrenal hormones.
Tuesday, June 28, 2016
Manufactured Stem Cells To Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Tuesday, June 28, 2016
Rates of Nonmedical Prescription Opioid Use Disorder Double in 10 Years
Researchers at NIH have found that the nonmedical use of prescription opioids has more than doubled among adults in the United States from 2001-2002 to 2012-2013.
Thursday, June 23, 2016
Peanut Allergy Prevention Strategy is Nutritionally Safe
Early-life peanut consumption does not affect duration of breastfeeding or children’s growth and nutrition.
Wednesday, June 22, 2016
NIH Launches Large Study of Pregnant Women in Areas Affected by Zika virus
Researchers at NIH and Fiocruz have begun a study to evaluate the magnitude of health risks that Zika virus infection poses to pregnant women and their developing fetuses and infants.
Wednesday, June 22, 2016
New Imaging Method May Predict Risk of Post-Treatment Brain Bleeding After Stroke
Researchers at NIH have developed technique that provides new insight into stroke.
Tuesday, June 21, 2016
Study Reveals Central Role of Endocannabinoids in Habit Formation
The new study findings point to a previously unknown mechanism in the brain that regulates the transition between goal-directed and habitual behaviors.
Tuesday, June 21, 2016
Predicting Effective Drug Combinations For TB
Researchers analyzed gene regulatory networks to explain the effectiveness of an experimental drug combination against drug-resistant tuberculosis bacteria.
Wednesday, June 15, 2016
Genomic Data Commons Launched
Part of the National Cancer Moonshot, the GDC will centralize and standardize accessible data.
Tuesday, June 07, 2016
Prevention May be Essential to Reducing Racial Disparities in Stroke
Researchers at NIH have found study provides clues to differences in stroke deaths between blacks and whites.
Friday, June 03, 2016
NIH Funds Biobank To Support Precision Medicine Initiative Cohort Program
$142 million over five years will be awarded to the Mayo Clinic to establish the world’s largest research-cohort biobank for the PMI Cohort Program
Friday, May 27, 2016
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Friday, May 27, 2016
New NIH-EPA Research Centers to Study Environmental Health Disparities
Scientists will partner with community organizations to study these concerns and develop culturally appropriate ways to reduce exposure to harmful environmental conditions.
Thursday, May 26, 2016
Nanoparticles Target, Transform Fat Tissue
Nanoparticles designed to target white fat and convert it to calorie-burning brown fat slowed weight gain in obese mice without affecting food intake. This proof-of-concept work could lead to new therapies to treat obesity.
Wednesday, May 25, 2016
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
A New Way Out for Stem Cells
Researchers at North Carolina State University have discovered that therapeutic stem cells exit the bloodstream in a different manner than was previously thought.
One Giant Leap for the Future of Safe Drug Delivery
Sheffield engineers make major breakthrough in developing silk ‘micro-rockets’ that can be used safely in biological environments.
Designing Potential AIDS Vaccine Candidates
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Anticancer Drug Stops Ebola Virus Molecule in its Tracks
A team of scientists from the University of Oxford have successfully mapped the structure of the Ebola virus molecule that drives the attack strategy and leads to fatal infections in humans.
Assessing the Effectiveness of Genome-Editing Technologies
Researchers have developed a cost-effective and rapid method for assessing edits generated by CRISPR-Cas9 and other genome-editing technologies.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!